Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Garima

      Articles By : Garima

      Novartis buys Takeda dry eye drug Xiidrafor for $3.4 billion

      Novartis buys Takeda dry eye drug Xiidrafor for $3.4 billion

      Garima9 May 2019 9:45 AM IST
      U.S: Swiss drugmaker Novartis AG said on Wednesday it agreed to acquire Takeda Pharmaceutical Company Ltd's dry eye drug Xiidrafor an upfront payment...
      Alphabets GV leads $58.5 million investment to launch Verve Therapeutics

      Alphabet's GV leads $58.5 million investment to launch Verve Therapeutics

      Garima9 May 2019 9:15 AM IST
      Verve Therapeutics plans to target adults at risk of coronary artery disease, the leading cause of death worldwide, by editing their genes to mirror...
      Alembic Pharma partners with SPH Group, Adia for Chinese market

      Alembic Pharma partners with SPH Group, Adia for Chinese market

      Garima8 May 2019 9:30 AM IST
      SPH Sine, Alembic Pharma and Adia will hold 51 per cent, 44 per cent and 5 per cent equity in the JVA.Vadodara: City-based Alembic Pharmaceuticals has...
      Medlife acquires medicine delivery startup Myra Medicines

      Medlife acquires medicine delivery startup Myra Medicines

      Garima7 May 2019 9:00 AM IST
      Myra's acquisition will enable the company to strengthen its pharma business and accrue profits, Medlife said in a statement.New Delhi: Health-tech...
      Aster DM Healthcare to infuse Rs 750 crore to add 1500 beds in four new hospitals

      Aster DM Healthcare to infuse Rs 750 crore to add 1500 beds in four new hospitals

      Garima6 May 2019 9:45 AM IST
      "We will be investing around Rs 750 crore to add 1,500 beds in the four hospitals we will be opening in India by the end of March 2022," Aster DM...
      Amgen, Syapse enters precision medicine collaboration in Oncology

      Amgen, Syapse enters precision medicine collaboration in Oncology

      Garima5 May 2019 9:30 AM IST
      Under the terms of the agreement, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need...
      Gilead Sciences posts higher Q1 profit; drug sales in line with expectations

      Gilead Sciences posts higher Q1 profit; drug sales in line with expectations

      Garima4 May 2019 9:00 AM IST
      Gilead Sciences said it still expects relatively flat full-year 2019 product sales of $21.3 billion to $21.8 billion.U.S: Gilead Sciences Inc on...
      Merck Q1 net profit up as cancer drug, vaccine sales soar

      Merck Q1 net profit up as cancer drug, vaccine sales soar

      Garima3 May 2019 9:00 AM IST
      Gardasil, a vaccine for preventing cancers associated with human papillomavirus, powered much of the earnings beat, helped by higher vaccination rates...
      AstraZeneca ties up with Transgene to develop viral immunotherapies

      AstraZeneca ties up with Transgene to develop viral immunotherapies

      Garima2 May 2019 9:25 AM IST
      AstraZeneca has been moving deeper into cancer therapy market through wide-ranging deals, including those for immunotherapy and targeted therapy.New...
      GSK expects shingles drug sales to exceed $1.3 billion

      GSK expects shingles drug sales to exceed $1.3 billion

      Garima2 May 2019 9:00 AM IST
      FTSE-100 member GSK, whose shares were up 0.3 per cent to 1,580 pence at 1156 GMT, also said it had decided to stop the clinical development of its...
      Biocon Q4 profit up 64 percent at Rs 214 crore

      Biocon Q4 profit up 64 percent at Rs 214 crore

      Garima30 April 2019 9:45 AM IST
      Bengaluru: Biotechnology major, Biocon Ltd recently announced its consolidated financial results for the fourth quarter and fiscal year ended March...
      Manipal bid to buyout Medanta for Rs 5800 crore: Report

      Manipal bid to buyout Medanta for Rs 5800 crore: Report

      Garima29 April 2019 12:20 PM IST
      MUMBAI: Cardiologist Naresh Trehan owned Medanta buyout is likely to conclude as TPG and Temasek-backed Manipal Hospitals has recently submitted a...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok